Pharmaceutical pricing and reimbursement
Pharmaceutical pricing and reimbursement

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Pharmaceutical pricing and reimbursement
  • European level rules on pricing and reimbursement of medicinal products
  • Regulatory framework
  • Transparency Directive
  • The Cross Border Healthcare Directive and health technology assessments
  • European Commission pricing and reimbursement initiatives
  • UK framework on pricing and reimbursement of medicinal products
  • Regulatory framework
  • National Health Service
  • Categories of medicinal products
  • More...

On 31 January 2020, the UK ceased to be an EU Member State and entered an implementation period during which it continues to be treated by the EU as a Member State for many purposes. As a third country, the UK can no longer participate in the EU’s political institutions, agencies, offices, bodies (except to the limited extent agreed), but it continues to be subject to EU law and must submit to the continuing jurisdiction of the Court of Justice of the EU in accordance with the transitional arrangements in Part 4 of the Withdrawal Agreement. For further reading, see: Brexit—Life Sciences and News Analysis: Brexit Bulletin—key updates, research tips and resources.

European level rules on pricing and reimbursement of medicinal products

The pricing and reimbursement of medicinal products and medical devices is not harmonised across the EU. This means that the national authorities of each Member State are free to decide how to set the price of medicinal products and the amount that will be reimbursed under their respective social security systems.

This lack of harmonisation has resulted in the EU Member States developing different schemes and policies, adapted to their own economic and healthcare needs. For example, in some EU Member States, a specific price or level of reimbursement must be approved, while in other Member States a system of direct or indirect controls on

Popular documents